NCT04072302View on ClinicalTrials.gov

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

November 29, 2017

Study Completion Date

November 29, 2017

Conditions
Malaria
Interventions
DRUG

KAF156

100 mg tablet, 20 mg tablet, 50 mg tablet

DRUG

Placebo

100 mg tablet, 20 mg tablet, 50 mg tablet

Trial Locations (1)

98109

Novartis Investigative Site, Seattle

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY